Formulary
Doravirine: Indications, Dosing, Side Effects and Interactions
Doravirine clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Doravirine: Indications, Dosing, Side Effects and Interactions
Doravirine clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**HIV-1 infection in combination with other antiretroviral drugs (initiated by a specialist)**
- **Adult** (By Mouth): 100 mg once daily.
Side effects
Common or very common Asthenia; diarrhoea; dizziness; drowsiness; gastrointestinal discomfort; gastrointestinal disorders; headache; hepatocellular injury; nausea; skin reactions; sleep disorders; vomiting Uncommon Anxiety; arthralgia; concentration impaired; confusion; constipation; depression; electrolyte imbalance; hypertension; malaise; memory loss; mood altered; muscle tone increased; myalgia; paraesthesia; suicidal ideation Rare or very rare Acute kidney injury; adjustment disorder; aggression; chest pain; chills; dyspnoea; hallucination; pain; rash pustular; renal disorder; thirst; tonsillar hypertrophy; urolithiases
Interactions
**Severe interactions:**
- Doravirine/lamivudine/tenofovir disoproxil should not be co-administered with medicinal products that are strong CYP3A enzyme inducers as significant decreases in doravirine plasma concentrations...
**Other interactions (57):**
- Delstrigo contains doravirine, lamivudine, and tenofovir disoproxil, therefore any interactions identified for these individually are relevant to Delstrigo and are presented in Table 1.
- Effects of other medicinal products on doravirine, lamivudine, and tenofovir disoproxil Doravirine Doravirine is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A...
- Co-administration with the moderate CYP3A inducer rifabutin decreased doravirine concentrations (see Table 1).
- When Delstrigo is co-administered with rifabutin, a 100 mg dose of doravirine should be given daily, approximately 12 hours after doravirine/lamivudine/tenofovir disoproxil dose (see section 4.2).
- Co-administration of doravirine/lamivudine/tenofovir disoproxil with other moderate CYP3A inducers has not been evaluated, but decreased doravirine concentrations are expected.
- If co-administration with other moderate CYP3A inducers (e.g., debrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, a 100 mg dose of doravirine...
Pregnancy
Manufacturer advises avoid-no information available.
Hepatic impairment
Manufacturer advises caution in severe impairment (no information available).
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Doravirine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

